Cerebrolysin Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: neurorecovery and cognitive outcomes research

Neuro Research peptide-complex Solution verified

Also known as: Cerebrolysin peptide complex

Open in Calculator ← Compound Index All Tools

Quick Facts

Reference Sizes

1 mL ampoule, 2 mL ampoule, 5 mL ampoule, 10 mL ampoule, 20 mL vial, 30 mL vial, 50 mL vial

Storage

Store in original carton at or below 25 deg C, protect from light, do not refrigerate or freeze, and use immediately after opening; single-use only

Solubility

Ready-to-use aqueous solution at 215.2 mg/mL; do not reconstitute and do not mix with incompatible or lipid-containing solutions

Catalog Description

Cerebrolysin is a proprietary 215.2 mg/mL aqueous mixture of low-molecular-weight porcine brain peptides and free amino acids. It is authorized in some countries for neurologic indications, but regulatory status varies and it is not FDA-approved in the United States. Individual trials report functional signals, while a 2023 Cochrane review found no mortality benefit in acute ischemic stroke and a possible increase in nonfatal serious adverse events.

Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.

Research Profile

Half-Life

Not meaningfully described by one half-life because Cerebrolysin is a heterogeneous peptide and amino-acid mixture

Onset

Trial outcomes were assessed from days to months; no single validated onset applies across indications

Administration Routes (Research)

IV infusionSlow IV injection up to 10 mLIM injection up to 5 mL

Reported Research Effects

Mixed stroke and neurorecovery findings
Some small randomized and observational studies report functional signals
Cochrane review found no mortality benefit and possible nonfatal-serious-event increase
Formulation-specific evidence

Reported Research Side Effects

Potential nonfatal serious-adverse-event increase in acute-stroke evidence synthesis
Fever agitation blood-pressure or heart-rate changes can occur especially with rapid administration
Hypersensitivity risk

Data source: Randomized trials, systematic review, and national regulatory records

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Protocols Reported in the Literature

30 mL daily [IV infusion; 10 consecutive days; Once daily]Source: randomized early-rehabilitation stroke study PMID 29362596
30 mL Monday-Friday [IV infusion; 4 weeks; Five days weekly]Source: randomized Alzheimer study PMID 11129744

Research Interactions

Flagged Avoid / Caution Combinations (Research)

Status epilepticus
Severe renal failure
MAO inhibitors or antidepressants without interaction review

Reflects patterns reported in research/community literature only. Not a safety guarantee, medical advice, or interaction warning for human use.

Research Notes

Official presentations include 1, 2, 5, and 10 mL ampoules and 20, 30, and 50 mL larger vials, though availability varies by country. Community storage in prefilled syringes conflicts with the official single-use immediate-administration instruction and carries contamination risk.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources

Cerebrolysin for acute ischaemic stroke — Cochrane Review via PubMed
https://pubmed.ncbi.nlm.nih.gov/37818733/

Cerebrolysin and early neurorehabilitation after acute ischemic stroke — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/29362596/

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.